georgeclerk
- Jefferies has downgraded Aadi Bioscience (NASDAQ:AADI) to hold following the recent announcement that a phase 2 study of Fyarro (nab-sirolimus) for solid tumors was unlikely to meeets its efficacy goal.
- The firm has a $1.50 price target (~3% downside based on Aug. 21 close) on the stock.
- Jefferies has removed projected revenue for the indication in solid tumors harboring TSC1 or TSC2 inactivating alterations.
- Fyarro is already approved for advanced malignant perivascular epithelioid cell tumors (PEComa), which brought in $6.2M in Q2.
